Interestingly, further studies with an inhibitor of CBFbeta-RUNX interaction resulted in EMT of breast cancer stem cells, suggesting that the loss of RUNX1 rather than increase of RUNX2 causes EMT in early stage breast cancer [72]. This evidence concerns the gene RUNX2 and breast cancer.